Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder; Post-traumatic stress disorders
- Focus Therapeutic Use
- 07 Jun 2017 Status changed from active, no longer recruiting to completed.
- 10 Jan 2017 Planned number of patients changed from 40 to 44.
- 10 Jan 2017 Planned End Date changed from 1 Sep 2016 to 1 Apr 2017.